Randomized trial demonstrates no reduction in cardiovascular events with rosuvastatin in hemodialysis patients, indicating limited cardiovascular benefit despite lowered cholesterol.
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)
No takes yet. Share an insight, caveat, or question.
Fellström et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: